AR022096A1 - Complejos estables de compuestos muy poco solubles - Google Patents

Complejos estables de compuestos muy poco solubles

Info

Publication number
AR022096A1
AR022096A1 ARP990104725A ARP990104725A AR022096A1 AR 022096 A1 AR022096 A1 AR 022096A1 AR P990104725 A ARP990104725 A AR P990104725A AR P990104725 A ARP990104725 A AR P990104725A AR 022096 A1 AR022096 A1 AR 022096A1
Authority
AR
Argentina
Prior art keywords
insoluble
soluble compounds
stable complexes
ionic polymers
compounds
Prior art date
Application number
ARP990104725A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26798138&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR022096(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR022096A1 publication Critical patent/AR022096A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Complejos estables insolubles en agua, de compuestos escasamente solubles, molecularmente dispersados en polímeros ionicos insolubles en agua. Lospolímeros ionicos insolubles de utilidad tienen un peso molecular superior a 80.000 D y una temperaturade transicion vítrea igual o superior a 50sC. Loscompuestos se microprecipitan en los polímeros ionicos en forma amorfa. Los complejos de acuerdo con la presente invencion aumentan significativamente labiodisponibilidad de compuestos terapéuticamenteactivos de escasa solubilidad.
ARP990104725A 1998-09-22 1999-09-20 Complejos estables de compuestos muy poco solubles AR022096A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10133698P 1998-09-22 1998-09-22
US13653199P 1999-05-28 1999-05-28

Publications (1)

Publication Number Publication Date
AR022096A1 true AR022096A1 (es) 2002-09-04

Family

ID=26798138

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP990104725A AR022096A1 (es) 1998-09-22 1999-09-20 Complejos estables de compuestos muy poco solubles
ARP110101253A AR080892A2 (es) 1998-09-22 2011-04-13 Complejo insoluble en agua, composicion farmaceutica que lo comprende, metodos para prepararla y metodo para preparar dicho complejo

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP110101253A AR080892A2 (es) 1998-09-22 2011-04-13 Complejo insoluble en agua, composicion farmaceutica que lo comprende, metodos para prepararla y metodo para preparar dicho complejo

Country Status (32)

Country Link
US (1) US6350786B1 (es)
EP (1) EP0988863B2 (es)
JP (5) JP2000095708A (es)
KR (1) KR100362019B1 (es)
CN (1) CN1201821C (es)
AR (2) AR022096A1 (es)
AT (1) ATE265232T1 (es)
AU (1) AU770745B2 (es)
BR (1) BR9904283A (es)
CA (1) CA2282906C (es)
CO (1) CO5140077A1 (es)
CZ (1) CZ300215B6 (es)
DE (1) DE69916733T3 (es)
DK (1) DK0988863T4 (es)
ES (1) ES2218918T5 (es)
HR (1) HRP990287B1 (es)
HU (1) HU228341B1 (es)
ID (1) ID24034A (es)
IL (1) IL131957A (es)
MA (1) MA26692A1 (es)
MY (1) MY124377A (es)
NO (1) NO326928B1 (es)
NZ (1) NZ337884A (es)
PE (1) PE20001049A1 (es)
PL (1) PL202757B1 (es)
PT (1) PT988863E (es)
RS (1) RS50193B (es)
RU (1) RU2240827C2 (es)
SG (1) SG97131A1 (es)
SI (1) SI0988863T2 (es)
TR (1) TR199902324A2 (es)
TW (1) TWI234465B (es)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1027886B1 (en) 1999-02-10 2008-07-09 Pfizer Products Inc. Pharmaceutical solid dispersions
US6440959B1 (en) * 1999-04-21 2002-08-27 Hoffman-La Roche Inc. Pyrazolobenzodiazepines
PE20010659A1 (es) * 1999-10-01 2001-06-20 Hoffmann La Roche Derivados de las pirimidin-2,4,6-trionas como inhibidores de metaloproteasas
US6313143B1 (en) * 1999-12-16 2001-11-06 Hoffmann-La Roche Inc. Substituted pyrroles
EP1301221B1 (en) * 2000-05-16 2006-02-15 Ortho-McNeil Pharmaceutical, Inc. Process for coating medical devices using super-critical carbon dioxide
US6469179B1 (en) 2000-10-03 2002-10-22 Hoffmann-La Roche Inc. Amorphous form of cell cycle inhibitor having improved solubility and bioavailability
US6482847B2 (en) 2000-10-03 2002-11-19 Hoffmann-La Roche Inc. Amorphous form of cell cycle inhibitor having improved solubility and bioavailability
US20050048126A1 (en) 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US6869617B2 (en) 2000-12-22 2005-03-22 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US7193084B2 (en) 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US6977085B2 (en) 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US6884436B2 (en) 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US6951656B2 (en) 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US6548531B2 (en) 2001-02-09 2003-04-15 Hoffmann-La Roche Inc. Method for cancer therapy
US6716845B2 (en) 2001-03-30 2004-04-06 Hoffmann-La Roche Inc. Barbituric acid derivatives
GB2392619B (en) * 2001-05-30 2004-10-20 Csir Method of encapsulating an active substance
US20030044514A1 (en) * 2001-06-13 2003-03-06 Richard Robert E. Using supercritical fluids to infuse therapeutic on a medical device
WO2002102373A1 (en) * 2001-06-15 2002-12-27 F. Hoffmann-La Roche Ag Method for administration of cancer therapeutic
WO2003000235A1 (en) 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions of dispersions of drugs and neutral polymers
KR20040011549A (ko) 2001-06-22 2004-02-05 화이자 프로덕츠 인크. 저용해도 및(또는) 산-민감성 약물 및 중화된 산성중합체를 포함하는 제약 조성물
JP2005504090A (ja) 2001-09-26 2005-02-10 バクスター・インターナショナル・インコーポレイテッド 分散体および溶媒相または液相の除去によるサブミクロンサイズ−ナノ粒子の調製
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
US7112340B2 (en) 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
US20030139373A1 (en) * 2001-11-20 2003-07-24 Breimer Lars Holger Method for cancer therapy
EP1469833B1 (en) 2002-02-01 2021-05-19 Bend Research, Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
DE60329188D1 (de) 2002-08-12 2009-10-22 Bend Res Inc Arzneizubereitungen bestehend aus arzneimitteln in halb-geordneter form und polymeren
DE10351087A1 (de) * 2003-10-31 2005-05-25 Bayer Technology Services Gmbh Feste Wirkstoff-Formulierung
CA2546115C (en) 2003-11-14 2013-01-08 Ajinomoto Co., Inc. Solid dispersions or solid dispersion pharmaceutical preparations of phenylalanine derivatives
EP1683525B1 (en) * 2003-11-14 2017-05-17 EA Pharma Co., Ltd. Sustained-release phenylalanine derivative preparation for oral administration
RU2411043C2 (ru) * 2004-04-01 2011-02-10 Юниверсите Де Льеж Фармацевтические композиции пиримидин-2,4,6-трионов
AR049915A1 (es) * 2004-06-14 2006-09-13 Anacor Pharmaceuticals Inc Compuestos con contenido de boro y metodos de uso de los mismos
WO2006062980A2 (en) * 2004-12-07 2006-06-15 Nektar Therapeutics Stable non-crystalline formulation comprising tiagabine
US20080063710A1 (en) * 2004-12-28 2008-03-13 Eisai R&D Management Co., Ltd. Rapidly Disintegrating Tablet and Production Method Thereof
WO2006073973A2 (en) * 2004-12-31 2006-07-13 Reddy Us Therapeutics, Inc. Novel benzylamine derivatives as cetp inhibitors
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
CA2596529C (en) * 2005-01-27 2014-08-19 Corium International, Inc. Hydrophilic biocompatible adhesive formulations and uses
EP1690528A1 (de) * 2005-02-11 2006-08-16 Abbott GmbH & Co. KG Herstellung von Dosierungsformen mit einer festen Dispersion eines mikrokristallinen Wirkstoffs
EP1885338A1 (en) * 2005-05-19 2008-02-13 Pfizer, Inc. Pharmaceutical compostions comprising an amorphous form of a vegf-r inhibitor
EP1767194A1 (de) * 2005-06-09 2007-03-28 Helm AG Verfahren zur Herstellung von Adsorbaten des Drospirenons
CN102206216B (zh) * 2005-06-22 2014-11-12 普莱希科公司 作为蛋白质激酶抑制剂的吡咯并[2,3-b]吡啶衍生物
US20080031944A1 (en) * 2006-08-04 2008-02-07 Cima Labs Inc. Stabilization of lorazepam
PE20080422A1 (es) * 2006-08-10 2008-04-28 Cipla Ltd Composicion solida antirretroviral de administracion oral
US20080107725A1 (en) * 2006-10-13 2008-05-08 Albano Antonio A Pharmaceutical Solid Dosage Forms Comprising Amorphous Compounds Micro-Embedded in Ionic Water-Insoluble Polymers
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
PE20081581A1 (es) * 2006-12-21 2008-11-12 Plexxikon Inc COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA
WO2008079909A1 (en) * 2006-12-21 2008-07-03 Plexxikon, Inc. Pyrrolo [2,3-b] pyridines as kinase modulators
WO2008081829A1 (ja) 2006-12-27 2008-07-10 Astellas Pharma Inc. 難水溶性薬物の溶解性維持用アミノアルキルメタアクリレートコポリマーｅ
CN101702878B (zh) * 2007-05-11 2012-11-28 弗·哈夫曼-拉罗切有限公司 可溶性差的药物的药物组合物
US8722736B2 (en) 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
US8426467B2 (en) 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
EP1997479A1 (en) * 2007-05-31 2008-12-03 Helm AG Stabilized amorphous candesartan cilexetil compositions for oral administration
JP2010533729A (ja) 2007-07-17 2010-10-28 プレキシコン，インコーポレーテッド キナーゼ調節のための化合物と方法、及びそのための適応
EP2214635A1 (en) * 2007-10-19 2010-08-11 Purdue Research Foundation Solid formulations of crystalline compounds
US8632805B2 (en) * 2008-06-20 2014-01-21 Mutual Pharmaceutical Company, Inc. Controlled-release formulations, method of manufacture, and use thereof
US7794750B2 (en) * 2008-06-20 2010-09-14 Mutual Pharmaceutical Company, Inc. Controlled-release formulations, method of manufacture, and use thereof
US20100099696A1 (en) * 2008-10-16 2010-04-22 Anthony Edward Soscia Tamper resistant oral dosage forms containing an embolizing agent
KR20100073454A (ko) * 2008-12-23 2010-07-01 국립암센터 트란스글루타미나제 억제제로 사용되는 신규한 피라졸로디아제핀계 화합물, 이의 제조방법 및 이를 포함하는 조성물
KR101739994B1 (ko) * 2009-04-03 2017-05-25 에프. 호프만-라 로슈 아게 프로판-１-술폰산 ｛３-［５-（４-클로로-페닐）-１Ｈ-피롤로［２，３-ｂ］피리딘-３-카르보닐］-２，４-디플루오로-페닐｝-아미드 조성물 및 그의 용도
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
NZ599866A (en) 2009-11-06 2014-09-26 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
US20130137739A1 (en) * 2010-05-31 2013-05-30 Astellas Pharma, Inc. Solid dispersion comprising triazole compound
KR101911972B1 (ko) 2011-02-07 2018-10-25 플렉시콘 인코퍼레이티드 키나제 조절을 위한 화합물 및 방법, 및 그에 대한 적응증
RU2013139701A (ru) 2011-02-17 2015-03-27 Ф. Хоффманн-Ля Рош Аг Способ контролируемой кристаллизации активного фармацевтического ингредиента из состояния переохлажденной жидкости экструзией горячего распада
TWI558702B (zh) 2011-02-21 2016-11-21 普雷辛肯公司 醫藥活性物質的固態形式
PL3135656T3 (pl) 2011-06-20 2019-07-31 H. Lundbeck A/S Deuterowane 1-piperazyno-3-fenyloindany do leczenia schizofrenii
US9199967B2 (en) 2011-08-18 2015-12-01 Dr. Reddy's Laboratories Ltd. Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (CETP) inhibitors
WO2013037396A1 (en) * 2011-09-12 2013-03-21 Bioneer A/S Solution of polymer in api for a solid dosage form
MX352074B (es) 2011-09-27 2017-11-08 Dr Reddys Laboratories Ltd Derivados de 5-bencilaminometil-6-aminopirazolo [3,4-b] piridina como inhibidores de proteina de transferencia de ester de colesterilo (cetp) utiles para el tratamiento de aterosclerosis.
BR122020010643B1 (pt) * 2011-10-14 2022-05-17 Array Biopharma Inc Dispersão sólida, composições farmacêuticas compreendendo a referida dispersão, usos das composições farmacêuticas e processo de preparação de uma dispersão sólida
WO2013142875A1 (en) * 2012-03-23 2013-09-26 Array Biopharma Inc. Treatment of brain cancer
US20140128431A1 (en) 2012-04-03 2014-05-08 Hoffmann-Laroche Inc. Pharmaceutical composition with improved bioavailability, safety and tolerability
EP2649989B1 (en) 2012-04-13 2017-10-18 King Saud University Method for preparing a solid dispersion, solid dispersion obtained thereby and use thereof
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
JO3339B1 (ar) * 2012-09-11 2019-03-13 Shanghai Inst Pharmaceutical Ind شكل مستقر غير متبلور من الأغوميلاتين وعملية تحضيره والتركيبات الدوائية التي تحتوي عليه
US20170071930A1 (en) 2012-11-19 2017-03-16 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions of cetp inhibitors
WO2014100418A2 (en) * 2012-12-20 2014-06-26 Kashiv Pharma, Llc Orally disintegrating tablet formulation for enhanced bioavailability
CN112353762A (zh) 2013-01-22 2021-02-12 霍夫曼-拉罗奇有限公司 具有改善的生物利用度的药物组合物
TWI615157B (zh) 2013-02-06 2018-02-21 大塚製藥股份有限公司 包括不定形西洛他唑的固體分散劑
WO2015038376A1 (en) * 2013-09-11 2015-03-19 3M Innovative Properties Company Coating compositions, dental structures thereof and methods for generating contrast
EP3076951B1 (en) * 2013-12-05 2020-09-30 Celal Albayrak Process for the production of drug formulations for oral administration
PT107846B (pt) * 2014-08-01 2019-03-22 Hovione Farm S A Produção de nano- partículas de dispersões sólidas amorfas por co-precipitação controlada
CA2987517A1 (en) * 2015-05-29 2016-12-08 Sun Pharmaceutical Industries Limited Oral pharmaceutical composition of isotretinoin
LT3447056T (lt) * 2016-12-13 2025-07-10 Transthera Sciences (Nanjing), Inc. Daugiafunkcių kinazių inhibitoriaus junginys ir jo kristalinė forma bei naudojimas
CA3060407A1 (en) 2017-04-28 2018-11-01 Seattle Genetics, Inc. Treatment of her2 positive cancers
KR102082775B1 (ko) * 2017-05-02 2020-02-28 주식회사 삼양바이오팜 수용해도 및 생체이용율이 개선된 조성물
RU2725879C2 (ru) * 2018-07-26 2020-07-07 Федеральное государственное бюджетное образовательное учреждение высшего образования "Казанский Государственный медицинский университет" Министерства здравоохранения Российской Федерации Интерполимерный носитель для пероральных систем контролируемой доставки активных фармацевтических ингредиентов
EP3891134A1 (en) 2018-12-03 2021-10-13 H. Lundbeck A/S Prodrugs of 4-((1r,3s)-6-chloro-3-phenyl-2,3-dihydro-1h-inden-1-yl)-1,2,2-trimethylpiperazine and 4-((1/r,3s)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1h-inden-1-yl)-2,2-dimethy-1-(methyl-d3)piperazine
TWI909513B (zh) 2019-01-25 2025-12-21 英屬開曼群島商百濟神州有限公司 作為ｂ-ｒａｆ激酶二聚體抑制劑之化合物及其製備方法
EP4714503A2 (en) 2020-01-24 2026-03-25 Handa Therapeutics, LLC Amorphous solid dispersions of dasatinib and uses thereof
CA3168680A1 (en) 2020-01-31 2021-08-05 Nanocopoeia, Llc Amorphous nilotinib microparticles and uses thereof
JP7705715B2 (ja) 2020-03-03 2025-07-10 デクセリアルズ株式会社 画像表示装置の製造方法
WO2021222739A1 (en) 2020-04-30 2021-11-04 Nanocopoeia, Llc Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
US11980619B2 (en) 2021-07-28 2024-05-14 Nanocopoeia, Llc Pharmaceutical compositions and crushable tablets including amorphous solid dispersions of dasatinib and uses

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS51118816A (en) * 1975-04-08 1976-10-19 Meiji Seika Kaisha Ltd A process for stabilizing non-crystalloidal solid
US4344934A (en) * 1978-11-20 1982-08-17 American Home Products Corporation Therapeutic compositions with enhanced bioavailability
DK569786A (da) * 1985-11-27 1987-05-28 Syntex Inc Benzimidazolderivater
GB8608080D0 (en) * 1986-04-02 1986-05-08 Fujisawa Pharmaceutical Co Solid dispersion composition
CZ280738B6 (cs) † 1988-02-10 1996-04-17 F. Hoffmann - La Roche And Co., Aktiengesellschaft Substituované pyrroly, jejich použití pro výrobu léčiv a léčiva na jejich bázi
JP2528706B2 (ja) † 1988-05-30 1996-08-28 ゼリア新薬工業株式会社 ジヒドロピリジン化合物の製剤組成物
USRE36736E (en) 1989-02-06 2000-06-13 Hoffman-La Roche Inc. Substituted pyrroles
JPH0729926B2 (ja) † 1989-07-25 1995-04-05 大塚製薬株式会社 易吸収性製剤用組成物
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
KR0182801B1 (ko) † 1991-04-16 1999-05-01 아만 히데아키 고체 분산체의 제조방법
US5281420A (en) 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
TW493991B (en) 1995-05-08 2002-07-11 Novartis Ag Pharmaceutical composition for oral administration of active agent having low water solubility and process for preparation of the same
GB9511220D0 (en) † 1995-06-02 1995-07-26 Glaxo Group Ltd Solid dispersions
BE1009856A5 (fr) * 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
US6254889B1 (en) * 1995-07-26 2001-07-03 Kyowa Hakko Kogyo Co., Ltd. Solid dispersion dosage form of amorphous xanthine derivative and enteric-coating polymer
CA2231050A1 (en) † 1995-09-07 1997-03-13 Biovail International Ltd. System for rendering substantially non-dissoluble bio-affecting agents bio-available
DE19548624A1 (de) 1995-12-23 1997-06-26 Boehringer Mannheim Gmbh Neue Barbitursäure-Derivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
JPH09208459A (ja) * 1996-02-07 1997-08-12 Eisai Co Ltd 溶解性を改良した製剤
DE69735057T2 (de) 1996-03-12 2006-08-31 PG-TXL Co., L.P., Houston Wasserlösliche paclitaxel-prodrogen
DE69730241T2 (de) * 1996-06-28 2005-08-11 Schering Corp. Feste lösung eines fungizids mit erhöhter bioverfügbarkeit
PE91598A1 (es) 1996-07-29 1998-12-24 Hoffmann La Roche Pirroles sustituidos
US6229011B1 (en) 1997-08-22 2001-05-08 Hoffman-La Roche Inc. N-aroylphenylalanine derivative VCAM-1 inhibitors
ES2203111T3 (es) 1998-03-17 2004-04-01 F. Hoffmann-La Roche Ag Maleimidas bisindol sustituidas para la inhibicion de proloferacion celular.

Also Published As

Publication number Publication date
JP6534979B2 (ja) 2019-06-26
MA26692A1 (fr) 2004-12-20
HK1026632A1 (en) 2000-12-22
DK0988863T4 (da) 2009-06-08
BR9904283A (pt) 2000-09-26
ID24034A (id) 2000-07-06
DE69916733D1 (de) 2004-06-03
CA2282906C (en) 2010-07-20
TR199902324A3 (tr) 2000-04-21
EP0988863B1 (en) 2004-04-28
PL202757B1 (pl) 2009-07-31
EP0988863B2 (en) 2009-03-18
DE69916733T3 (de) 2009-09-24
CZ330499A3 (cs) 2000-04-12
JP2007224048A (ja) 2007-09-06
US6350786B1 (en) 2002-02-26
EP0988863A3 (en) 2000-08-09
HUP9903189A2 (hu) 2000-06-28
CN1201821C (zh) 2005-05-18
SI0988863T2 (sl) 2009-08-31
NZ337884A (en) 2001-02-23
CO5140077A1 (es) 2002-03-22
IL131957A (en) 2005-06-19
HU9903189D0 (en) 1999-11-29
MY124377A (en) 2006-06-30
JP2015187170A (ja) 2015-10-29
ES2218918T3 (es) 2004-11-16
JP2013035875A (ja) 2013-02-21
CN1251312A (zh) 2000-04-26
ES2218918T5 (es) 2009-06-23
JP6253135B2 (ja) 2017-12-27
NO994583D0 (no) 1999-09-21
TR199902324A2 (xx) 2000-04-21
YU47399A (es) 2002-08-12
HRP990287A2 (en) 2000-06-30
HRP990287B1 (en) 2004-12-31
HUP9903189A3 (en) 2009-07-28
CA2282906A1 (en) 2000-03-22
SG97131A1 (en) 2003-07-18
NO326928B1 (no) 2009-03-16
PL335592A1 (en) 2000-03-27
PE20001049A1 (es) 2000-10-17
PT988863E (pt) 2004-07-30
SI0988863T1 (en) 2004-08-31
DE69916733T2 (de) 2005-03-31
JP2000095708A (ja) 2000-04-04
KR100362019B1 (ko) 2002-11-23
TWI234465B (en) 2005-06-21
JP2016196515A (ja) 2016-11-24
AU4880799A (en) 2000-03-23
CZ300215B6 (cs) 2009-03-18
AR080892A2 (es) 2012-05-16
DK0988863T3 (da) 2004-08-30
KR20000023426A (ko) 2000-04-25
RS50193B (sr) 2009-05-06
HU228341B1 (en) 2013-03-28
NO994583L (no) 2000-03-23
RU2240827C2 (ru) 2004-11-27
ATE265232T1 (de) 2004-05-15
AU770745B2 (en) 2004-03-04
IL131957A0 (en) 2001-03-19
EP0988863A2 (en) 2000-03-29

Similar Documents

Publication Publication Date Title
AR022096A1 (es) Complejos estables de compuestos muy poco solubles
DE69123795D1 (de) Pharmazeutische Zusammensetzung zur rektalen Verabreichung von Wirkstoffen mit topischer medizinischer Wirkung im Dickdarmniveau
MX9205895A (es) Derivados de taxol solubles en agua.
BR9901782A (pt) Forma para dosagem de nefazodona.
CY1108626T1 (el) Ιαματικες συνθεσεις που περιεχουν ασπιρινη
PT948357E (pt) Utilizacao de amino alcoois de baixo peso molecular em composicoes oftalmicas
IS4067A (is) PEG-Interferonafleiður, aðferð til framleiðslu þeirra, og notkunar sem lyfja
ITMI911149A0 (it) Composizioni farmaceutiche in forma di schiuma per somministrazione intravaginale, cutanea e orale
CY1113387T1 (el) Υδατοδιαλυτα συμπλοκα σιδηρου υδατανθρακα, η παρασκευη αυτων και φαρμακα, τα οποια περιεχουν αυτα
DK2130554T3 (da) Albuminfrie faktor VIII-præparater
PA8578601A1 (es) Derivados de 2,2- difenil-benzodioxol
ES2058503T5 (es) Formulaciones farmaceuticas para uso parenteral.
YU46012B (sh) Postupak za izradu vodenih gelirajućih rastvora derivata arilpropionske kiseline koji mogu da se resporbuju kroz kožu
ATE309998T1 (de) Pharmazeutisch wirksamer sulfonamid derivaten
ATE509938T1 (de) Makrolidverbindungen mit antiinflammatorischer wirkung
PT799046E (pt) Solucoes estaveis de 2-cloro-2'-desoxiadenosina
UY27419A1 (es) Formulaciones en combinación de derivados de 1,4-benzotiepina-1,1-dioxido con otras sustancias activas, y su utilización.
DZ3196A1 (fr) Dérivés d'acide indolyl-3-glyoxyle à bonnes proprietes thérapeutiques.
IT9020944A1 (it) Composizioni farmaceutiche orali liquide ad attivita' antiinfiammatoria
DE60023647D1 (de) Makrolide mit entzündungshemmender wirkung
MX9305230A (es) Utilizacion de ciertos surfactantes anionicos para mejorarla efectividad antimicrobiana de composiciones oftalmicas.
CY1108197T1 (el) Βελτιωμενες φαρμακευτικες συνταγοποιησεις αναστολεων πρωτεασης hiv
CY1105849T1 (el) Χρηση αντισηπτικων στην εμπορικη κατασκευη φαρμακευτικου παρασκευασματος προς αποτροπη ή θepαπεια εναντι φλεγμονων εντος του ανθρωπινου σωματος
TR200102008T2 (tr) Serebral işemi profilaksı ve tedavisi için piridin türevlerinin kullanımı.
TR200001909T2 (tr) Matris metaloprotez inhibitörleri.

Legal Events

Date Code Title Description
FC Refusal